Published in Hepatitis Weekly, June 30th, 1997
The study, reported by Tatsuo Kanda and colleagues, agrees with many other recent reports finding no clinical impact for the newly discovered hepatitis G virus (HGV) or GBV-C ("Detection of GBV-C RNA in Patients with Non-A-E Fulminant Hepatitis by Reverse-Transcription Polymerase Chain Reaction," Hepatology, June 1997;25(5):1261-1266).
Fulminant hepatitis is characterized by severe liver damage, hepatic encephalopathy, and high mortality. Fulminant hepatic failure was originally defined as the development of hepatic encephalopathy within eight weeks...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.